{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:15:09Z","timestamp":1770236109729,"version":"3.49.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Hong Kong Research Grants Council","award":["Projects C1007-15G and 11200715"],"award-info":[{"award-number":["Projects C1007-15G and 11200715"]}]},{"DOI":"10.13039\/100007567","name":"City University of Hong Kong","doi-asserted-by":"publisher","award":["Project 7004862"],"award-info":[{"award-number":["Project 7004862"]}],"id":[{"id":"10.13039\/100007567","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12859-018-2093-6","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T06:52:56Z","timestamp":1520405576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Prediction of sensitivity to gefitinib\/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-4493","authenticated-orcid":false,"given":"Bin","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor H. F.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"2093_CR1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129\u201339.","journal-title":"N Engl J Med"},{"key":"2093_CR2","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2093_CR3","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497\u2013500.","journal-title":"Science"},{"key":"2093_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1742-4658.2009.07448.x","volume":"277","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010;277:301\u20138.","journal-title":"FEBS J"},{"key":"2093_CR5","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1038\/modpathol.3801018","volume":"21","author":"M Ladanyi","year":"2008","unstructured":"Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008;21:S16\u201322.","journal-title":"Mod Pathol"},{"key":"2093_CR6","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","volume":"29","author":"M Fukuoka","year":"2011","unstructured":"Fukuoka M, Wu Y-L, Thongprasert S, Sunpaweravong P, Leong S-S, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non\u2013small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866\u201374.","journal-title":"J Clin Oncol"},{"key":"2093_CR7","doi-asserted-by":"crossref","unstructured":"C. Zhou, Y.-L. Wu, G. Chen, J. Feng, X.-Q. Liu, C. Wang, et al, \"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study,\" Lancet Oncol, 12, 735\u2013742, 2011.","DOI":"10.1016\/S1470-2045(11)70184-X"},{"key":"2093_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u201346.","journal-title":"Lancet Oncol"},{"key":"2093_CR9","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","volume":"26","author":"Y-L Wu","year":"2015","unstructured":"Wu Y-L, Zhou C, Liam C-K, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26:1883\u20139.","journal-title":"Ann Oncol"},{"key":"2093_CR10","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","volume":"30","author":"J-Y Han","year":"2012","unstructured":"Han J-Y, Park K, Kim S-W, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30:1122\u20138.","journal-title":"J Clin Oncol"},{"key":"2093_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u201357.","journal-title":"N Engl J Med"},{"key":"2093_CR12","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380\u20138.","journal-title":"N Engl J Med"},{"key":"2093_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121\u20138.","journal-title":"Lancet Oncol"},{"key":"2093_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","volume":"12","author":"ME Arcila","year":"2013","unstructured":"Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12:220\u20139.","journal-title":"Mol Cancer Ther"},{"key":"2093_CR15","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S1470-2045(11)70129-2","volume":"13","author":"H Yasuda","year":"2012","unstructured":"Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012;13:e23\u201331.","journal-title":"Lancet Oncol"},{"key":"2093_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","volume":"8","author":"GR Oxnard","year":"2013","unstructured":"Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8:179\u201384.","journal-title":"J Thorac Oncol"},{"key":"2093_CR17","doi-asserted-by":"publisher","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","volume":"5","author":"H Yasuda","year":"2013","unstructured":"Yasuda H, Park E, Yun C-H, Sng NJ, Lucena-Araujo AR, Yeo W-L, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5:216ra177.","journal-title":"Sci Transl Med"},{"key":"2093_CR18","doi-asserted-by":"publisher","first-page":"7854","DOI":"10.1158\/0008-5472.CAN-06-1951","volume":"66","author":"M Inukai","year":"2006","unstructured":"Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non\u2013small cell lung cancer. Cancer Res. 2006;66:7854\u20138.","journal-title":"Cancer Res"},{"key":"2093_CR19","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.","journal-title":"PLoS Med"},{"key":"2093_CR20","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, J\u00e4nne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non\u2013small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786\u201392.","journal-title":"N Engl J Med"},{"key":"2093_CR21","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-04-2618","volume":"11","author":"M Taron","year":"2005","unstructured":"Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005;11:5878\u201385.","journal-title":"Clin Cancer Res"},{"key":"2093_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2005.05.017","volume":"50","author":"R Rosell","year":"2005","unstructured":"Rosell R, Ichinose Y, Taron M, Sarries C, Queralt C, Mendez P, et al. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer. 2005;50:25\u201333.","journal-title":"Lung Cancer"},{"key":"2093_CR23","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2005.01.388","volume":"23","author":"S-W Han","year":"2005","unstructured":"Han S-W, Kim T-Y, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non\u2013small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23:2493\u2013501.","journal-title":"J Clin Oncol"},{"key":"2093_CR24","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1158\/1078-0432.CCR-15-1046","volume":"21","author":"Y Kobayashi","year":"2015","unstructured":"Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, et al. EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first-or third-generation TKIs. Clin Cancer Res. 2015;21:5305\u201313.","journal-title":"Clin Cancer Res"},{"key":"2093_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/annonc\/mdt418","volume":"25","author":"M Beau-Faller","year":"2014","unstructured":"Beau-Faller M, Prim N, Ruppert A-M, Nanni-Met\u00e9llus I, Lacave R, Lacroix L, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014;25:126\u201331.","journal-title":"Ann Oncol"},{"key":"2093_CR26","doi-asserted-by":"crossref","unstructured":"Cheng C, Wang R, Li Y, Pan Y, Zhang Y, Li H, et al. EGFR exon 18 mutations in east Asian patients with lung adenocarcinomas: a comprehensive investigation of prevalence, clinicopathologic characteristics and prognosis. Sci Rep. 2015;5:13959. https:\/\/www.nature.com\/articles\/srep13959 .","DOI":"10.1038\/srep13959"},{"key":"2093_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/JTO.0000000000000048","volume":"9","author":"S Watanabe","year":"2014","unstructured":"Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, et al. Effectiveness of gefitinib against non\u2013small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014;9:189\u201394.","journal-title":"J Thorac Oncol"},{"key":"2093_CR28","first-page":"3885","volume":"35","author":"T Otsuka","year":"2015","unstructured":"Otsuka T, MORI M, Yano Y, Uchida J, Nishino K, Kaji R, et al. Effectiveness of tyrosine kinase inhibitors in Japanese patients with non-small cell lung cancer harboring minor epidermal growth factor receptor mutations: results from a multicenter retrospective study (HANSHIN oncology group 0212). Anticancer Res. 2015;35:3885\u201391.","journal-title":"Anticancer Res"},{"key":"2093_CR29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/JTO.0000000000000504","volume":"10","author":"C-H Chiu","year":"2015","unstructured":"Chiu C-H, Yang C-T, Shih J-Y, Huang M-S, Su W-C, Lai R-S, et al. Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X\/L861Q\/S768I mutations. J Thorac Oncol. 2015;10:793\u20139.","journal-title":"J Thorac Oncol"},{"key":"2093_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jtho.2015.12.107","volume":"11","author":"B Klughammer","year":"2016","unstructured":"Klughammer B, Brugger W, Cappuzzo F, Ciuleanu T, Mok T, Reck M, et al. Examining treatment outcomes with Erlotinib in patients with advanced non\u2013small cell lung cancer whose Tumors Harbor uncommon EGFR mutations. J Thorac Oncol. 2016;11:545\u201355.","journal-title":"J Thorac Oncol"},{"key":"2093_CR31","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1073\/pnas.0502860102","volume":"102","author":"EL Kwak","year":"2005","unstructured":"Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 2005;102:7665\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2093_CR32","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1073\/pnas.0709662105","volume":"105","author":"C-H Yun","year":"2008","unstructured":"Yun C-H, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong K-K, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci. 2008;105:2070\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"2093_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.compbiomed.2014.06.016","volume":"63","author":"L Ma","year":"2015","unstructured":"Ma L, Wang DD, Huang Y, Wong MP, Lee VH, Yan H. Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties. Comput Biol Med. 2015;63:293\u2013300.","journal-title":"Comput Biol Med"},{"key":"2093_CR34","doi-asserted-by":"crossref","unstructured":"Ma L, Wang DD, Zou B, Yan H. An eigen-binding site based method for the analysis of anti-EGFR drug resistance in lung cancer treatment. IEEE\/ACM Trans. Comput. Biol. Bioinform. 2017;14(5):1187\u2013194. http:\/\/ieeexplore.ieee.org\/abstract\/document\/7469333\/ .","DOI":"10.1109\/TCBB.2016.2568184"},{"key":"2093_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12953-016-0102-0","volume":"14","author":"L Ma","year":"2016","unstructured":"Ma L, Zou B, Yan H. Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics. Proteome Sci. 2016;14:12.","journal-title":"Proteome Sci"},{"key":"2093_CR36","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1038\/srep02855","volume":"3","author":"DD Wang","year":"2013","unstructured":"Wang DD, Zhou W, Yan H, Wong M, Lee V. Personalized prediction of EGFR mutation-induced drug resistance in lung cancer. Sci Rep. 2013;3:2855.","journal-title":"Sci Rep"},{"key":"2093_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.cplett.2016.04.056","volume":"652","author":"B Zou","year":"2016","unstructured":"Zou B, Wang DD, Ma L, Chen L, Yan H. Analysis of the relationship between lung cancer drug response level and atom connectivity dynamics based on trimmed Delaunay triangulation. Chem Phys Lett. 2016;652:117\u201322.","journal-title":"Chem Phys Lett"},{"key":"2093_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1021\/jm400378w","volume":"57","author":"OP van Linden","year":"2013","unstructured":"van Linden OP, Kooistra AJ, Leurs R, de Esch IJ, de Graaf C. KLIFS: a knowledge-based structural database to navigate kinase\u2013ligand interaction space. J Med Chem. 2013;57:249\u201377.","journal-title":"J Med Chem"},{"key":"2093_CR39","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1016\/j.bmcl.2011.09.027","volume":"21","author":"S Mordalski","year":"2011","unstructured":"Mordalski S, Kosciolek T, Kristiansen K, Sylte I, Bojarski AJ. Protein binding site analysis by means of structural interaction fingerprint patterns. Bioorg Med Chem Lett. 2011;21:6816\u20139.","journal-title":"Bioorg Med Chem Lett"},{"key":"2093_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1021\/jm030331x","volume":"47","author":"Z Deng","year":"2004","unstructured":"Deng Z, Chuaqui C, Singh J. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein\u2212 ligand binding interactions. J Med Chem. 2004;47:337\u201344.","journal-title":"J Med Chem"},{"key":"2093_CR41","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1021\/jm050381x","volume":"49","author":"Z Deng","year":"2006","unstructured":"Deng Z, Chuaqui C, Singh J. Knowledge-based design of target-focused libraries using protein\u2212 ligand interaction constraints. J Med Chem. 2006;49:490\u2013500.","journal-title":"J Med Chem"},{"key":"2093_CR42","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1021\/ci300200r","volume":"53","author":"V Chupakhin","year":"2013","unstructured":"Chupakhin V, Marcou G, Baskin I, Varnek A, Rognan D. Predicting ligand binding modes from neural networks trained on protein\u2013ligand interaction fingerprints. J Chem Inf Model. 2013;53:763\u201372.","journal-title":"J Chem Inf Model"},{"key":"2093_CR43","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1021\/ci900043r","volume":"49","author":"VI P\u00e9rez-Nueno","year":"2009","unstructured":"P\u00e9rez-Nueno VI, Rabal O, Borrell JI, Teixid\u00f3 J. APIF: a new interaction fingerprint based on atom pairs and its application to virtual screening. J Chem Inf Model. 2009;49:1245\u201360.","journal-title":"J Chem Inf Model"},{"key":"2093_CR44","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.bmcl.2013.12.017","volume":"24","author":"J Witek","year":"2014","unstructured":"Witek J, Smusz S, Rataj K, Mordalski S, Bojarski AJ. An application of machine learning methods to structural interaction fingerprints\u2014a case study of kinase inhibitors. Bioorg Med Chem Lett. 2014;24:580\u20135.","journal-title":"Bioorg Med Chem Lett"},{"key":"2093_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1021\/jm049312t","volume":"48","author":"C Chuaqui","year":"2005","unstructured":"Chuaqui C, Deng Z, Singh J. Interaction profiles of protein kinase\u2212 inhibitor complexes and their application to virtual screening. J Med Chem. 2005;48:121\u201333.","journal-title":"J Med Chem"},{"key":"2093_CR46","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1021\/ci800441c","volume":"49","author":"AM Wassermann","year":"2009","unstructured":"Wassermann AM, Geppert H, Bajorath J r. Searching for target-selective compounds using different combinations of multiclass support vector machine ranking methods, kernel functions, and fingerprint descriptors. J Chem Inf Model. 2009;49:582\u201392.","journal-title":"J Chem Inf Model"},{"key":"2093_CR47","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nsb0902-646","volume":"9","author":"M Karplus","year":"2002","unstructured":"Karplus M, McCammon JA. Molecular dynamics simulations of biomolecules. Nat Struct Mol Biol. 2002;9:646\u201352.","journal-title":"Nat Struct Mol Biol"},{"key":"2093_CR48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1109\/TNN.2007.901277","volume":"19","author":"H Lu","year":"2008","unstructured":"Lu H, Plataniotis KN, Venetsanopoulos AN. MPCA: multilinear principal component analysis of tensor objects. IEEE Trans Neural Netw. 2008;19:18\u201339.","journal-title":"IEEE Trans Neural Netw"},{"key":"2093_CR49","doi-asserted-by":"crossref","unstructured":"Kobayashi Y, Mitsudomi T. Not all EGFR mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107(9):1179\u2013186. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5021039\/ .","DOI":"10.1111\/cas.12996"},{"key":"2093_CR50","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res. 2000;28:235\u201342.","journal-title":"Nucleic Acids Res"},{"key":"2093_CR51","first-page":"1","volume":"16","author":"L Ma","year":"2015","unstructured":"Ma L, Wang DD, Huang Y, Yan H, Wong MP, Lee VH. EGFR mutant structural database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib. BMC Bioinf. 2015;16:1.","journal-title":"BMC Bioinf"},{"key":"2093_CR52","unstructured":"Faith J. Interactive data exploration with targeted projection pursuit, Leonardo Electronic Almanac. 2009;16:6\u20137. http:\/\/nrl.northumbria.ac.uk\/2706\/ ."},{"key":"2093_CR53","doi-asserted-by":"crossref","unstructured":"Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2010;39(suppl_1):D945\u2013D950. https:\/\/academic.oup.com\/nar\/article\/39\/suppl_1\/D945\/2508687 .","DOI":"10.1093\/nar\/gkq929"},{"key":"2093_CR54","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1002\/ijc.30691","volume":"140","author":"Z Yang","year":"2017","unstructured":"Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, et al. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis. Int J Cancer. 2017;140:2805\u201319.","journal-title":"Int J Cancer"},{"key":"2093_CR55","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1634\/theoncologist.2014-0154","volume":"20","author":"M Burotto","year":"2015","unstructured":"Burotto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist. 2015;20:400\u201310.","journal-title":"Oncologist"},{"key":"2093_CR56","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.critrevonc.2013.08.003","volume":"89","author":"G Bronte","year":"2014","unstructured":"Bronte G, Rolfo C, Giovannetti E, Cicero G, Pauwels P, Passiglia F, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol. 2014;89:300\u201313.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2093_CR57","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/B978-0-12-381270-4.00019-6","volume":"487","author":"A Leaver-Fay","year":"2011","unstructured":"Leaver-Fay A, Tyka M, Lewis SM, Lange OF, Thompson J, Jacak R, et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 2011;487:545.","journal-title":"Methods Enzymol"},{"key":"2093_CR58","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11:3696\u2013713.","journal-title":"J Chem Theory Comput"},{"key":"2093_CR59","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/jcc.540150503","volume":"15","author":"R Abagyan","year":"1994","unstructured":"Abagyan R, Totrov M, Kuznetsov D. ICM\u2014a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. J Comput Chem. 1994;15:488\u2013506.","journal-title":"J Comput Chem"},{"key":"2093_CR60","doi-asserted-by":"publisher","first-page":"325","DOI":"10.6026\/97320630009325","volume":"9","author":"M Radifar","year":"2013","unstructured":"Radifar M, Yuniarti N, Istyastono EP. PyPLIF: python-based protein-ligand interaction fingerprinting. Bioinformation. 2013;9:325.","journal-title":"Bioinformation"},{"key":"2093_CR61","doi-asserted-by":"crossref","unstructured":"Smith TC, Frank E. Introducing machine learning concepts with WEKA. Statistical Genomics: Methods and Protocols. 2016:353\u201378. https:\/\/link.springer.com\/protocol\/10.1007\/978-1-4939-3578-9_17 .","DOI":"10.1007\/978-1-4939-3578-9_17"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-018-2093-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T05:57:58Z","timestamp":1570859878000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-018-2093-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2093"],"URL":"https:\/\/doi.org\/10.1186\/s12859-018-2093-6","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"11 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"88"}}